Figure 2
From: Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations
CTC and overall survival. (a) Survival analysis of PDAC patients with 0.3–3 CTC in the blood (blue, N = 23, MS 20 months) versus those with >3 CTC/ml blood (red dots, N = 16, MS 11.5 months; P = 0.12). (b) Survival analysis of PDAC patients with CTC containing a KRAS G12V mutation (MS 24.5 months) and other KRAS mutations (MS 10 months; P = 0.21).
